Continue reading this on our app for a better experience

Open in App
Home News Healthcare

Boehringer Ingelheim to acquire assets, IP from Singapore biotech firm in deal worth more than US$1 bil

Stanislaus Jude Chan
Stanislaus Jude Chan • 2 min read
Boehringer Ingelheim to acquire assets, IP from Singapore biotech firm in deal worth more than US$1 bil
The deal is the largest for any biotech company in Singapore, and among the biggest globally for preclinical stage programmes.
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.